Video

Dr. Liao on Outcomes With Ivosidenib in Advanced Cholangiocarcinoma

Chih-Yi Liao, MD, discusses outcomes reported with ivosidenib in patients with advanced cholangiocarcinoma.

Chih-Yi Liao, MD, assistant professor of medicine, University of Chicago Department of Medicine, discusses outcomes reported with ivosidenib (Tibsovo) in patients with advanced cholangiocarcinoma.

In the phase 3 ClarIDHy trial (NCT02989857), the agent was examined vs placebo in patients with IDH1-mutant, advanced cholangiocarcinoma. The primary end point of the trial was progression-free survival (PFS), which was met, according to Liao. Ivosidenib resulted in a PFS of 2.7 months vs 1.4 months with placebo in this population, Liao says. Although this may not seem numerically significant, it translates a 63% reduction in the risk of progression or death, Liao notes.

In terms of overall survival (OS), the median OS in patients who received treatment with ivosidenib was 10.3 months vs 7.5 months in those who were given placebo, Liao adds. Despite the numeric improvement, this was not found to be statistically significant, Liao concludes.

Related Videos
James J. Harding, MD, associate attending physician, Memorial Sloan Kettering Cancer Center
J. Bradley Elder, MD
Rimas V. Lukas, MD
Adam E. Singer, MD, PhD, Health Sciences Clinical Instructor, medicine, division lead, kidney cancer, Division of Hematology/Oncology, UCLA Health
Diane Reidy-Lagunes, MD, vice chair, Oncology Operations, Regional Care Network, Memorial Sloan Kettering Cancer Center
Shubham Pant, MD, MBBS
Kevin Kalinsky, MD, MS, professor, Department of Hematology and Medical Oncology, director, Division of Medical Oncology, Department of Hematology and Medical Oncology, Emory University School of Medicine; Louisa and Rand Glenn Family Chair in Breast Cancer Research, director, Glenn Family Breast Center, director, Breast Medical Oncology, Winship Cancer Institute of Emory University
Brett L. Ecker, MD
Benjamin Garmezy, MD, assistant director, Genitourinary Research, Sarah Cannon Research Institute
Yelena Y. Janjigian, MD, chief, Gastrointestinal Oncology Service, Memorial Sloan Kettering Cancer Center